Intuniv is expected to be made available in November 2009 in 1mg, 2mg, 3mg, and 4mg dosage strengths. For more information call (800) 536-7878 or visit www.intuniv.com. Related Content.

Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch, with "closely aligned" consumer ...

Shire plc, the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of an investigational once-daily medication ...

ZUG, Switzerland, March 30, 2017 /PRNewswire/ --A NewNon-stimulantClinicalOption forChildren andAdolescentsFrom 6 to 17Years oldWith ADHD Shire pl ...

Patient materials for Shire’s ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA’s Division of Drug Marketing, ...

INTUNIV, a once-daily guanfacine formulation, is the first nonscheduled, selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.